To describe laboratory abnormalities among HIVćinfected women and their infants with standard and increased lopinavir/ritonavir (LPV/r) dosing during the third trimester of pregnancy. Methods: We evaluated data on pregnant women from NISDI cohorts (2002ć2009) enrolled in Brać zil, who received at least 28 days of LPV/r during the third pregnancy trimester and gave birth to singleton infants. Results: 164 women received LPV/r standard dosing [(798/198 or 800/200 mg/ day) (Group 1)] and 70 increased dosing [(> 800/200 mg/day) (Group 2)]. Group 1 was more likely to have advanced clinical disease and to use ARVs for treatment, and less likely to have CD4 counts ≥ 500 cells/mm 3 . Mean plasma viral load was higher in Group 2. here were statistically signiić cant, but not clinically meaningful, diferences between groups in mean AST, ALT, cholesterol, and triglycerides. he proportion of women with Grade 3 or 4 adverse events was very low, with no statistically signiicant diferences between groups in severe adverse events related to ALT, AST, total bilirubin, cholesterol, or triglycerides. here were statistically signiicant, but not clinically meaningć ful, diferences between infant groups in ALT and creatinine. he proportion of infants with Grade 3 or 4 adverse events was very low, and there were no statistically signiicant diferences in severe adverse events related to ALT, AST, BUN, or creatinine. Conclusion: he proportions of women and infants with severe laboratory adverse events were very low. Increased LPV/r dosing during the third trimester of pregnancy appears to be safe for HIVćinfected women and their infants.
INTRODUCTION
Motherćtoćchild transmission (MTCT) is the primary means by which children acquire HIV infection. Development and implementation of e cacious interventions to prevent MTCT (including antiretroviral [ARV] prophylaxis, cesarean section before labor and before rupć ture of membranes, and complete avoidance of breastfeeding), along with use of antiretroviral treatment by HIVćinfected pregnant women who meet criteria for treatment, have resulted in the virtual elimination of MTCT in several areas of the world. 1 Several national guidelines recommend combination antiretroviral regimens for preć vention of MTCT of HIV and for the treatć ment of maternal HIV infection itself. 2ć4 he combination of zidovudine (ZDV), lamivudine (3TC), and lopinavir/ritonavir (LPV/r) has beć come a common ARV regimen for prevention of MTCT of HIV in Brazil and other countries.
In our analysis of data from he Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) International Site Development Initiative (NISDI) Perinatal Protocol, we examined the association between maternal ARV regimens used during pregnancy and infant preterm birth and low birth weight. 5 Although use of a protease inhibitorćcontaining regimen durć ing pregnancy was not associated with an inć creased risk of these adverse infant outcomes, we emphasized the importance of monitoring HIVćinfected women and their children for potential adverse events associated with mać ternal use of ARVs during pregnancy. Recentć ly, McArthur et al. 6 reported twin preterm neć onates with cardiac toxicity related to LPV/r. he twins were born preterm (32 weeks gestać tion) to an HIVćinfected mother. One of them developed complete heart block and dilated cardiomiopathy, while the other developed mild bradycardia.
Este é um artigo Open Access sob a licença de CC BY-NC-ND During pregnancy, changes in drug pharmacokić netics are induced through physiological variations. 7ć12 Increased progesterone levels tend to affect drug absorpć tion, which also may be impaired by higher gastric pH. Drug distribution is modified by elevated body water and fat, while increased renal blood flow may enhance the clearance of some drugs. Plasma albumin and alphaćacid glycoprotein concentrations are decreased, potentially afć fecting protein binding. There may be concomitantly inć creased distribution, metabolism and excretion. 13 Finally, the expression of cytochrome Pć450 is highly variable during pregnancy, 14 with potential consequences for the metabolism of many drugs, including protease inhibitors (PIs). Transplacental passage of PIs is generally low and cord blood PI concentrations are undetectable in most inć fants born to mothers receiving PIs. 15 Plasma concentrations of LPV/r are reduced durć ing the third trimester of gestation [Area Under the Curve (AUC) and trough levels (C min )]. 7ć10,12 Thus, an inć crease in LPV/r dose during the third trimester for both LPV/rćexperienced and ćnaïve HIVćinfected pregnant women or serum therapeutic drug monitoring (TDM) 2ć 3, 12 have been endorsed by some experts. In a recent United Statesćbased study, Best et al. 16 suggested that the higher LPV/r dose should be used in second and third trimester pregnant women, especially those who are PIćexperienced, and that postpartum LPV/r dosing can be reduced to standard dosing within two weeks after deć livery. However, higher dosing during the third trimester could be associated with the development of toxicities afć fecting both mother and infant, leading to lower adherć ence. There is limited information regarding maternal and infant adverse events with higher third trimester dosć ing. The objective of this study was to describe the occurć rence of laboratory adverse events according to standard and increased LPV/r dosing during the third trimester of pregnancy in HIVćinfected women and their infants.
MATERIAL AND METHODS
he study population comprised HIVćinfected pregć nant women enrolled in the Eunice Kennedy Shriver National Institute of Child Health and Human Developć ment (NICHD) International Site Development Initiative (NISDI) Perinatal or Longitudinal Study in Latin American Countries (LILAC) protocols, who received LPV/r during the third trimester of pregnancy, and their infants. he NISDI Perinatal and NISDI LILAC protocols are prospecć tive cohort studies that enrolled HIVćinfected pregnant women and their infants at multiple sites in Argentina, the Bahamas, Brazil, Jamaica, Mexico, and Peru beginning in 2002 (NISDI Perinatal) and in 2008 (NISDI LILAC). 17 Parć ticipant followćup continued for at least six months a! er delivery/birth (last maternal laboratory assays obtained at 6ć12 weeks postpartum in the NISDI Perinatal Protoć col). Choice and dosing of ARVs was at the discretion of each subject's physician. All women enrolled in the studć ies provided written informed consent, and the protocols were approved at local institutional review boards (IRBs), as well as the IRBs at NICHD and Westat.
Since the majority (61%) of the NISDI/LILAC enrollć ments occurred in Brazil and few subjects at sites in the other countries used increased dosing of LPV/r, data were only analyzed for participants from Brazil. Other inclusion criteria were: enrolled through December 31 st , 2009; irst onćstudy pregnancy; known pregnancy outcome that was a singleton birth; reached the third trimester of pregnancy; used LPV/r in the third trimester for at least 28 days; and received LPV/r standard [798/198 mg/day (so! gel capć sules) or 800/200 mg/day (hard capsules)] or increased doses (> 800/200 mg/day) during the third trimester.
Maternal and infant adverse events were assessed acć cording to standard or increased LPV/r dosages durć ing the third trimester. Statistical analyses for categorical comparisons were performed using the Fisher's exact test and the Student's t test for comparison of means. Analyses were performed using SAS statistical so! ware version 9.1; pćvalues < 0.05 were considered to be signiicant.
RESULTS
Overall, 1,630 pregnancies occurred among women enć rolled in the cohorts through the end of 2009, 1,000 of whom were from Brazil. Of these, 966 women were enrolled for the irst time and had known pregnancy outcomes. Of the 966 subjects, 944 used ARVs during the third trimesć ter of pregnancy and had singleton births. Of these, 291 used LPV/r during the third trimester, and 234 subjects received standard or increased doses of LPV/r for at least 28 days. herefore, the study population comprised 234 HIVćinfected women and their infants. Of the 234 women, 164 (70.1%) used standard LPV/r dosing (Group 1) (medić an duration of use: 76 days) and 70 (29.9%) used increased dosing (Group 2) (median duration of use: 67 days).
Maternal variables are presented in Tables 1 and 2 . Mothć ers in Group 1 were older than those in Group 2 (p = 0.002). A larger proportion of women in Group 1 compared to Group 2 were classiied as CDC clinical disease stage B/C at both enrollment and hospital discharge (p = 0.0008 and p = 0.002, respectively). A larger proportion of mothers in Group 1 received ARVs for treatment (vs. prophylaxis) than in Group 2 (p = 0.02). A smaller proportion of women in Group 1 than Group 2 had CD4 counts of 500 cells/mm 3 or more at enrollment (p = 0.04) ( Table 1) . Although the proportion of subjects with a CD4 count at enrollment of 500 cells/mm 3 or more difered by group, the mean CD4 count did not difer between groups at enrollment or at hospital discharge (p > 0.2) (Table 2) , and, although the mean plasma viral load was signiicantly higher in Group 2 at enrollment (p = 0.007) and at the hospital discharge (p = 0.0002) ( Table 2) , there were no statistically signiicant diferences in the percentages of subjects with viral loads ≥ 1,000 copies/mL at enrollment or at hospital discharge. Similarly, the percentage of subjects whose plasma viral load decreased from enrollment to hospital discharge was not diferent between groups (Table 1) . At enrollment, women in Group 2 had higher mean choć lesterol values (p = 0.03). At 6ć12 weeks postpartum, women in Group 1 had higher mean alanine aminotransferase (ALT) (p = 0.001), aspartate aminotransferase (AST) (p = 0.02), and triglyceride (p = 0.01) values ( Table 2) . he overall proporć tion of women with Grade 3 or 4 adverse events was very low (! 1.5%, except cholesterol 8.6%), and there were no statistić cally signiicant diferences between the proportions of women in each group with Grade 3 or 4 adverse events related to ALT, AST, total bilirubin, cholesterol, or triglycerides (Table 1) .
Infant variables are shown in Tables 3 and 4 . here were no statistically signiicant diferences in gestać tional age, birth weight, gender, or HIV infection stać tus according to standard versus increased dose of LPV/r ( Table 3 ). As shown in Table 4 , infants born to mothers in Group 1 had signiicantly higher mean ALT values at birth (p = 0.0006), and creatinine values at birth and at 6ć12 weeks (p < 0.0001). he overall proportion of infants with Grade 3 or 4 adverse events was very low (! 1.9%), and there were no stać tistically signiicant diferences in the proportions of infants in each group with Grade 3 or 4 adverse events related to ALT, AST, blood urea nitrogen (BUN), or creatinine (Table 3) . 
DISCUSSION
Since most studies of LPV/r have been performed in reć sourcećrich settings, among ARVćnaïve, nonćpregnant adults or ARVćexperienced subjects, extrapolation to other populations may be limited by diferences in genetics, diet, concomitant comorbidities, and other factors. For this reać son, we undertook this analysis of laboratory adverse events among HIVćinfected pregnant women and their infants in Brazil according to LPV/r dosing during the third trimesć ter of pregnancy. In this analysis, most women (70.1%) used standard LPV/r dosing during the third trimester of pregć nancy and the median duration of use of either standard or increased dosing of LPV/r was over two months. Womć en in the standard dosing group were more likely to have more advanced clinical disease and to have used ARVs for treatment. They were less likely to have CD4 counts of 500 cells/mm 3 or more. he mean plasma viral load was higher in the increased dosing group. Although there were statistically signiicant diferences between groups in terms of mean AST, ALT, cholesterol, and triglyceride values, none of these diferences were clinically meaningful. he overć all proportion of women with Grade 3 or 4 adverse events was very low, and there were no statistically signiicant difć ferences in the proportions of women in each group with severe adverse events related to ALT, AST, total bilirubin, cholesterol, or triglycerides. Although there were statistić cally signiicant diferences between infant groups in terms of ALT and creatinine values, none of these diferences were clinically meaningful. he overall proportion of infants with Grade 3 or 4 adverse events was very low, and there were no statistically signiicant diferences in the proportions of infants in each group with severe adverse events related to ALT, AST, BUN, or creatinine. Lipid abnormalities and elevations in liver enzyme conć centrations have been associated with use of LPV/r. Like other PIs, LPV/r may cause signiicant lipid elevations and fat redistribution. Hypertriglyceridemia and hypercholesć terolemia were the most frequently observed laboratory abć normalities in LPV/r recipients in clinical trials and may be the reason for discontinuation of therapy in some HAARTć experienced patients. 18 Increases in total cholesterol and triglycerides are seen within the irst month of starting therapy and are relatively stable ater this time. 19 Tot a l Grade 3 and 4 cholesterol and triglyceride elevations appear to occur more frequently in PI-experienced than in PI-naive LPV/r-treated patients. Some trials have found that the lipid derangements caused by LPV/r were more severe than those caused by other PIs such as atazanavir, atazanavir/ritonavir, or nelinavir, 20,21 but other trials reported similar elevations in triglycerides and cholesterol in LPV/r recipients as compared to subjects receiving other PIs. 22 PIs including LPV/r have been associated with insulin resistance, new onset diabetes, and worsening of preexisting diabetes requiring hypoglycemic agents in some patients. LPV/r can cause transient elevations in transaminase levels, but these are usually not clinically meaningful. he incidence of severe hepatic events in patients receiving LPV/r is very low. Hepatitis C coinfection and baseline elevations in transaminases may be associated with severe liver events in LPV/r recipients. 23 Robbins et al. 24 published data showing that doses of LPV/r higher than those currently approved by the FDA are safe and well tolerated for up to 48 weeks in children and adolescents with HIV infection. here was no signiicant increase in plasma triglycerides, and while there was an initial statistically signiicant increase in cholesterol, this was of modest size and did not worsen over the course of the study. here was no evidence of hepatic or cardiac toxicity with these higher doses.
A French study explored whether LPV/r exposure during pregnancy was associated with adverse outcomes. 25 For each HIV-infected woman, two uninfected women matched by age, parity and geographical origin were selected among patients delivering during the same period. Rates of placental complications and gestational glucose intolerance were not higher among HIV-infected women than in controls. However, the rate of preterm birth was higher among HIV-infected women (21%) than among controls (10%) (p < 0.01).
One of the strengths of our study is that it is a large multicenter cohort that includes prospectively collected data. Women and children were enrolled and followed at the same health care facility at each site, where they received primary HIV and other medical care, and it is unlikely that any important clinical and laboratory events were missed among those retained in care. he observational study design is a limitation, in that women were prescribed LPV/r standard dose vs. higher dose by their physicians (and not by randomization). In addition, the women enrolled in Group 1 on average were older, more likely to be using ARVs for treatment (rather than prophylaxis), and appeared to have more advanced HIV disease (more women at CDC clinical disease stage B/C at both enrollment and hospital discharge) than women in Group 2. However, given the low adverse event rates for both mothers and infants in the entire study population, these baseline diferences between the two dose groups are unlikely to afect the main indings of our analysis. Finally, adherence data were not collected as part of the Perinatal Protocol (2002-2007, but were during the LILAC Protocol (2008-current).
In summary, in this population of HIV-infected women and their infants in Brazil, the proportions of subjects with severe laboratory adverse events were very low. These results suggest that increased LPV/r dosing during the third trimester of pregnancy is safe for both HIV-infected women and their infants. Further assessments of LPV/r dosing during pregnancy and maternal/ infant adverse events are warranted.
